Choe Won-Taek, Murray Michael T, Stidham Katrina R, Roberson Joseph B
California Ear Institute in E. Palo Alto, E. Palo Alto, California, USA.
Otol Neurotol. 2007 Dec;28(8):1022-5. doi: 10.1097/MAO.0b013e318155a4d3.
To analyze the efficacy of Ciprodex otic augmented with N-acetylcysteine (NAC) against difficult ear infections.
Subjects were selected with at least 1 month of continuous otorrhea despite at least 3 distinct medical or surgical treatments.
Subjects received Ciprodex otic augmented with 0.5 or 2% NAC using standard dosing schemes.
Serial audiometry and cessation of otorrhea by both history and binocular microscopy.
Seven subjects were included with an average of 18.4 months of continuous otorrhea despite aggressive therapy. Cessation of otorrhea was achieved in 6 of 7 subjects generally within 4 weeks of treatment. One of these 6 subjects remains on chronic suppressive therapy. The remaining subject failed because of persistent noncompliance. No subjects demonstrated ototoxicity via pretreatment and posttreatment audiometry.
Ciprodex otic augmented with NAC seems to have considerable efficacy against otherwise refractory ear infections. This technique may prove to be a simple and powerful option for the treatment of difficult ear infections.
分析用N - 乙酰半胱氨酸（NAC）增强的环丙沙星耳用制剂治疗难治性耳部感染的疗效。
选取尽管接受了至少3种不同的药物或手术治疗但仍有至少1个月持续性耳漏的患者。
受试者使用标准给药方案接受添加了0.5%或2% NAC的环丙沙星耳用制剂治疗。
通过连续听力测定以及根据病史和双目显微镜检查判断耳漏停止情况。
纳入7名受试者，尽管进行了积极治疗，但平均仍有18.4个月的持续性耳漏。7名受试者中有6名在治疗后4周内实现了耳漏停止。这6名受试者中有1名仍在接受慢性抑制治疗。其余1名受试者因持续不依从治疗而失败。通过治疗前和治疗后的听力测定，未发现受试者出现耳毒性。
添加NAC的环丙沙星耳用制剂似乎对难治性耳部感染具有显著疗效。该技术可能被证明是治疗难治性耳部感染的一种简单而有效的选择。
